Lung cancer incidence in never smokers

European journal of Clinical and Medical Oncology

Volumn 2, Issue 2, 2010, Pages

  Clément Duchêne, Christelle ^a   Wakelee, Heather ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor (EGFR) mutations; Lung cancer; Never smokers; Second hand smoke exposure

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; BEVACIZUMAB; CARBOPLATIN; CARCINOGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYBRID PROTEIN; K RAS PROTEIN; PACLITAXEL; PLACEBO; PROTEIN EML4 ALK; PROTEIN P53; RADON; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHEMICAL CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; DIETARY INTAKE; DNA POLYMORPHISM; ENVIRONMENTAL EXPOSURE; EPSTEIN BARR VIRUS; FAMILY HISTORY; GENE MUTATION; GENETIC RISK; HORMONE SUBSTITUTION; HUMAN; INDOOR AIR POLLUTION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; NONHUMAN; OCCUPATIONAL EXPOSURE; PASSIVE SMOKING; PROGRESSION FREE SURVIVAL; REVIEW; RISK ASSESSMENT; SMOKING; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 77956488057     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nature Rev Cancer. 2007;7(10):778-790.
4. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 0710;2025(5):561-570.
5. Toh CK, Lim WT. Lung cancer in never-smokers. J Clin Pathol. 2007; 60(4):337-340.
6. Scagliotti GV, Longo M, Novello S. Nonsmall cell lung cancer in never smokers. Curr Opin Oncol. 2009;21(2):99-104.
7. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol. 2003;4(1): 45-55.
8. Guérin S, Hill C. Cancer epidemiology in France in 2010, comparison with the USA. Bull Cancer. 2010;97(1):47-54.
9. Morbidity and Mortality Weekly Report. Available at www.cdc.gov/mmwr (accessed November 2009).
10. Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol. 2007;25(5):472-478.
11. Boffetta P, Järvholm B, Brennan P, Nyrén O. Incidence of lung cancer in a large cohort of non-smoking men from Sweden. Int J Cancer. 2001; 94(4):591-593.
12. Zell JA, Ou SH, Ziogas A, Anton-Culver H. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol. 2005;23(33): 8396-8405.
13. Yano T, Miura N, Takenaka T, et al. Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer. 2008;113(5):1012-1018.
14. Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst. 2006; 98(10):691-699.
15. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321:323-329.
16. Nyberg F, Agudo A, Boffetta P, Fortes C, González CA, Pershagen G. A European validation study of smoking and environmental tobacco smoke exposure in nonsmoking lung cancer cases and controls. Cancer Causes Control. 1998;9(2):173-82.
17. Wells AJ, English PB, Posner SF, Wagenknecht LE, Perez-Stable EJ. Misclassification rates for current smokers misclassified as nonsmokers. Am J Public Health. 1998;88(10):1503-1509.
18. Hu J, Mao Y, Dryer D, White K; Canadian Cancer Registries Epidemiology Research Group. Risk factors for lung cancer among Canadian women who have never smoked. Cancer Detect Prev. 2002;26(2): 129-138.
19. Brennan P, Fortes C, Butler J, et al. A multicenter case-control study of diet and lung cancer among non-smokers. Cancer Causes Control. 2000; 11(1):49-58.
20. Wakai K, Ando M, Ozasa K, et al. Updated information on risk factors for lung cancer: findings from the JACC Study. J Epidemiol. 2005; 15(Suppl 2):S134-139.
21. Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst. 2004;96(2):99-106.
22. Vineis P, Hoek G, Krzyzanowski M, et al. Lung cancers attributable to environmental tobacco smoke and air pollution in non-smokers in different European countries: a prospective study. Environ Health. 2007; 6:7.
23. Wu, A. Carcinogenic effects. In: Shopland DR, Zeise L, Dunn A, eds. Health Effects of Exposure to Environmental Tobacco Smoke. Bethesda, MD: National Cancer Institute; 1999.
24. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1.
25. Hirayama T. Non-smoking wives of heavy smokers have a higher risk of lung cancer: a study from Japan. BMJ. 1981;282(6259):183-185.
26. Trichopoulos D, Kalandidi A, Sparros L, Mac-Mahon B. Lung cancer and passive smoking. Int J Cancer. 1981;27(1):1-4.
27. Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009;15(18):5626-5645.
28. Jockel KH, Pohlabeln H, Ahrens W, Krauss M. Environmental tobacco smoke and lung cancer. Epidemiology. 1998;9(6):672-675.
29. Nyberg F, Agrenius V, Svartengren K, Svensson C, Pershagen G. Environmental tobacco smoke and lung cancer in nonsmokers: does time since exposure play a role? Epidemiology. 1998;9(3):301-308.
30. Zhong L, Goldberg MS, Gao YT, Jin F. A case-control study of lung cancer and environmental tobacco smoke among nonsmoking women living in Shanghai, China. Cancer Causes Control. 1999;10(6):607-616.
31. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol. 1996;144(6):554-562.
32. Gorlova OY, Weng SF, Zhang Y, Amos CI, Spitz MR. Aggregation of cancer among relatives of never-smoking lung cancer patients. Int J Cancer. 2007;121(1):111-118.
33. Etzel CJ, Amos CI, Spitz MR. Risk for smoking related cancer among relatives of lung cancer patients. Cancer Res. 2003;63(23):8531-8535.
34. Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet. 2004;75(3):460-474.
35. Gorlova OY, Weng SF, Zhang Y, Amos CI, Spitz MR, Wei Q. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1322-1328.
36. Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst. 1994;86(11):869-870.
37. Kabat GC, Miller AB, Rohan TE. Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer. 2007;120(10):2214-2220.
38. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE. Hormonal factors and risk of lung cancer among women? Int J Epidemiol. 2003;32(2):263-271.
39. Wu AH, Yu MC, Thomas DC, Pike MC, Henderson BE. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. Cancer Res. 1988;48(24 Pt 1):7279-7284.
40. Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of nonsmall cell lung cancer in women. J Clin Oncol. 2007;25(36):5785-5792.
41. Neuberger JS, Field RW. Occupation and lung cancer in nonsmokers. Rev Environ Health. 2003;18(4):251-267.
42. Pohlabeln H, Boffetta P, Ahrens W, et al. Occupational risks for lung cancer among nonsmokers. Epidemiology. 2000;11(5):532-538.
43. Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer. 1987;40(5):604-609.
44. Wang TJ, Zhou BS, Shi JP. Lung cancer in nonsmoking Chinese women: a case-control study. Lung Cancer. 1996;14(Suppl 1):S93-98.
45. Shen XB, Wang GX, Huang, YZ, Xiang, LS, Wang XH. Analysis and estimates of attributable risk factors for lung cancer in Nanjing, China. Lung Cancer. 1996;14(Suppl 1):S107-112.
46. Zhao Y, Wang S, Aunan K, Seip HM, Hao J. Air pollution and lung cancer risks in China: a meta-analysis. Sci Total Environ. 2006;366(2-3): 500-513.
47. Ernster VL. Female lung cancer. Annu Rev Public Health. 1996;17:97-114.
48. Teixeira E, Conde S, Alves P, Ferreira L, Figueirede A, Parente B. Lung cancer and women. Rev Port Pneumol. 2003;9(3):225-247.
49. Cardenas VM, Thun MJ, Austin H, et al. Environmental tobacco smoke and lung cancer mortality in the American Cancer Society's Cancer Prevention Study II. Cancer Causes Control. 1997;8(1):57-64.
50. Chen Y, Zhi G, Feng Y, et al. Measurements of black and organic carbon emission factors for household coal combustion in China: implication for emission reduction. Environ Sci Technol. 2009;43(24):9495-9500.
51. Liu Q, Sasco AJ, Riboli E, Hu MX. Indoor air pollution and lung cancer in Guangzhou, People's Republic of China. Am J Epidemiol. 1993;137(2): 145-154.
52. Hinds MW, Cohen HI, Kolonel LN. Tuberculosis and lung cancer risk in nonsmoking women. Am Rev Respir Dis. 1982;125(6):776-778.
53. Lubin JH, Boice J, Jr., Edling C. A Joint Analysis of 11 Underground Miners Studies. Bethesda, MD: National Institutes of Health; 1994.
54. WHO Handbook on Indoor Radon: A Public Health Perspective. Available at www.WHO.int.
55. Sandler DP, Weinberg CR, Shore DL, et al. Indoor radon and lung cancer risk in Connecticut and Utah. J Toxicol Environ Health A. 2006;69(7):633-654.
56. Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case- control studies. BMJ. 2005;330(7485):223.
57. Krewski D, Lubin JH, Zielinski JM, et al. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology. 2005;16(2):137-145.
58. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer. 2004; 101(6):1428-1436.
59. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 2001;61(7):2799-2803.
60. Lim WT, Chuah KL, Leong SS, Tan EH, Toh CK. Assessment of human papillomavirus and Epstein-Barr virus in lung adenocarcinoma. Oncol Rep. 2009;21(4):971-975.
61. Leroux C, Girard N, Cottin V, Greenland T, Mornex JF, Archer F. Jaagsiekte sheep retrovirus (JSRV): from virus to lung cancer in sheep. Vet Res. 2007;38 (2):211-228.
62. Toh CK, Gao F, Lim WT, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006; 24(15):2245-2251.
63. Clément-Duchêne C, Vignaud JM, Stoufflet A, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer. 2010;67(2):144-150.
64. Brownson RC, Loy TS, Ingram E, et al. Lung cancer in nonsmoking women. Histology and survival patterns. Cancer. 1995;75(1):29-33.
65. Yang P, Cerhan JR, Vierkant RA, et al. Adenocarcinoma of the lung is strongly associated with cigarette smoking: further evidence from a prospective study of women. Am J Epidemiol. 2002;156(12):1114-1122.
66. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006;130(6):1796-1802.
67. Muscat JE, Wynder EL. Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett. 1995;88(1):1-5.
68. Dibble R, Langeburg W, Bair S, Ward J, Akerley W. Natural history of non-small cell lung cancer in nonsmokers. J Clin Oncol. 2005;23:abstract 7252.
69. Epplein M, Schwartz SM, Potter JD, Weiss NS. Smoking-adjusted lung cancer incidence among Asian-Americans (United States). Cancer Causes Control. 2005;16(9):1085-1090.
70. Ou SI, Ziogas A, Zell JA. Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): high percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity. J Clin Oncol. 2008;26:abstract 8004.
71. Wakelee HA, Chang ET, Shema SJ, et al. Survival after non-small cell lung cancer in never-smoking Asian/Pacific Islander and Latina women. J Thorac Oncol. 2009;4(9 Suppl 1):S310(abstract A7.6).
72. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354(4): 333-342.
73. Pinsky PF. Racial and ethnic differences in lung cancer incidence: how much is explained by differences in smoking patterns? (United States). Cancer Causes Control.2006;17(8):1017-1024.
74. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004;126(2):347-351.
75. Itaya T, Yamaoto N, Ando M, et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci. 2007; 98(2):226-230.
76. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest. 2007;132(1):185-192.
77. Yoshino I, Kawano D, Oba T, Yamazaki K, Kometani T, Maehara Y. Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg. 2006;81(4):1189-1193.
78. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006;106(11):2428-2436.
79. Yano T, Miura N, Takenaka T, et al. Surgical results of non-small cell lung cancer in never-smokers as a separate entity. J Clin Oncol. 2008;26: 398s.
80. Subramanian J, Velcheti V, Gao F, Govindan R. Presentation and stagespecific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2(9):827-830.
81. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306-13311.
82. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006;24(11):1700-1704.
83. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer. 2007;7(3):169-181.
84. Toyooka S, Matsuo K, Shigematsu H, et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res. 2007;13(19): 5763-5768.
85. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153):561-566.
86. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4- ALK. J Clin Oncol. 2009;27(26):4247-4253.
87. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006;12(5):1647-1653.
88. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339-346.
89. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14(18):5731-5734.
90. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009;15(18):5714-5723.
91. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer. Clin Cancer Res. 2008;14(10):2895-2899.
92. Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005;65(12):5076-5083.
93. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat. 2003;21(3):229-239.
94. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev. 1999; 8(4 Pt 1):297-302.
95. Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 2009; 15(18):5646-5661.
96. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133-144.
97. Shaw AT, Costa D, Mino-Kenudson M, et al. Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol. 2009;27(15s):abstract 11021.
98. Shaw AT, Costa DB, Iafrate AJ, et al. Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations. J Thorac Oncol. 2009;4(9 Suppl 1):S305-6:abstract A6.4.
99. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2): 123-132.
100. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
101. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
102. NCT00446225. Available at http://clinicaltrials.gov. Last update Jan 23, 2010.
103. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892-5899.